0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Neurology |

This Month in Archives of Neurology FREE

Arch Neurol. 2012;69(1):11-12. doi:10.1001/archneurol.2011.1434.
Text Size: A A A
Published online

OUTCOME MEASURES USED IN PEDIATRIC STROKE STUDIES: A SYSTEMATIC REVIEW

Engelmann and JordanArticle designed a systematic review of the literature to survey the current use of pediatric stroke outcome measures. Studies that used at least 1 standardized measure to assess the outcome of children with ischemic or hemorrhagic stroke, from full-term newborn to age 18 years, were included.

INTRANASAL INSULIN THERAPY FOR ALZHEIMER DISEASE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: A PILOT CLINICAL TRIAL

Craft and colleaguesArticle examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease. They find that treatment with 20 IU of insulin improved delayed memory (P < .05) and that both doses of insulin (20 and 40 IU) preserved caregiver-rated functional ability (P < .01).

AUTOSOMAL RECESSIVE CAUSES LIKELY IN EARLY-ONSET ALZHEIMER DISEASE

Wingo and colleaguesArticle determine the genetic contribution to non–autosomal dominant early-onset Alzheimer disease (EOAD) (onset age ≤60 years) cases and identify the likely mechanism of inheritance in those cases. The most likely explanation of the data is that approximately 90% of EOAD cases are due to autosomal recessive causes.

ASSESSING RESPONSE TO STROKE THROMBOLYSIS: VALIDATION OF 24-HOUR MULTIMODAL MAGNETIC RESONANCE IMAGING

Campbell and colleaguesArticle compare assessment of the effect of reperfusion therapies using 24-hour vs day 90 magnetic resonance imaging. They find that assessment of final infarct volume using diffusion-weighted imaging at 24 hours captures the effect of reperfusion therapies on infarct growth and predicts functional outcome similarly to imaging at day 90.

STATINS AND INTRACEREBRAL HEMORRHAGE: A RETROSPECTIVE COHORT STUDY

Hackam et alArticle examine the association between statins and intracerebral hemorrhage (ICH) in patients with recent ischemic stroke in a population-based setting. They report that statin exposure following ischemic stroke was not associated with ICH. Editorial perspective is provided by Philip B. Gorelick, MD, MPHArticle.

 Image not available.

Subgroup analyses. Risk for intracerebral hemorrhage (ICH) in relation to statin exposure in predefined subgroups. Squares indicate hazard ratios (HRs); whiskers, 95% confidence intervals; and SES, socioeconomic status.

EFFECTS OF AGE AND AMYLOID DEPOSITION ON AΒ DYNAMICS IN THE HUMAN CENTRAL NERVOUS SYSTEM

Huang et alArticle investigate whether dynamic changes in Aβ levels in the human central nervous system may be altered by aging or by the pathology of Alzheimer disease (AD) and thus contribute to the risk of AD. They show that a reduction in the linear increase in the Aβ levels in cerebrospinal fluid (CSF) samples that is associated with amyloid deposition and a decreased CSF Aβ diurnal pattern associated with increasing age disrupt the normal physiology of Aβ dynamics and may contribute to AD.

DIFFUSION TENSOR IMAGING IN ACUTE OPTIC NEUROPATHIES: PREDICTOR OF CLINICAL OUTCOMES

Naismith et alArticle evaluate directional diffusivities within the optic nerve in a first event of acute optic neuritis to determine whether decreased axial diffusivity (AD) would predict 6-month visual outcome and optic nerve integrity measures. Decreased AD in acute optic neuritis was associated with a worse 6-month visual outcome and correlated with visual evoked potential and retinal nerve fiber layer measures of axon and myelin injury. Axial diffusivity may serve as a marker of axon injury in acute white matter injury.

11C-PIB IMAGING OF HUMAN IMMUNODEFICIENCY VIRUS–ASSOCIATED NEUROCOGNITIVE DISORDER

A nces and colleaguesArticle evaluate whether the amyloid-binding agent carbon 11–labeled Pittsburgh Compound B ([11C]-PiB) could differentiate Alzheimer disease (AD) from human immunodeficiency virus (HIV)–associated neurocognitive disorder (HAND) in middle-aged HIV-positive participants. They show that middle-aged HIV-positive participants, even with HAND, do not exhibit increased 11C-PiB levels, whereas symptomatic AD individuals have increased fibrillar Aβ42 deposition in cortical and subcortical regions.

DACLIZUMAB USE IN PATIENTS WITH PEDIATRIC MULTIPLE SCLEROSIS

Gorman et alArticle report the use of daclizumab in pediatric-onset multiple sclerosis (POMS). They find that daclizumab may be a safe and at least partially effective treatment option for patients with POMS with disease activity despite first-line disease-modifying therapy.

IMPACT OF INFLAMMATION ON BRAIN VOLUME IN MULTIPLE SCLEROSIS

Cheriyan and colleaguesArticle study changes in brain volume measured monthly in patients treated for relapsing multiple sclerosis (MS) due to loss of tissue and the appearance of inflammation. They find that 2 major changes in brain volume occur in patients with relapsing MS, a steady decrease likely due to tissue loss with overlapping transient increases due to the appearance of inflammation.

LARGE, NONPLATEAUING RELATIONSHIP BETWEEN CLINICAL DISABILITY AND CEREBRAL WHITE MATTER LESION LOAD IN PATIENTS WITH MULTIPLE SCLEROSIS

Caramanos et alArticle characterize the relationship between cerebral white matter lesion load (CWM-LL) and clinical disability. They find that a large, nonplateauing relationship exists between CWM-LL and Expanded Disability Status Score–measured clinical disability when patients with multiple sclerosis are studied to examine the entire range of disability, minimize nonbiological sources of variability, and increase pathologic specificity.

PROTEOMIC CHANGES IN CEREBROSPINAL FLUID OF PRESYMPTOMATIC AND AFFECTED PERSONS CARRYING FAMILIAL ALZHEIMER DISEASE MUTATIONS

Ringman and colleaguesArticle compared proteomic profiles of cerebrospinal fluid (CSF) from individuals with familial Alzheimer disease (FAD) who were mutation carriers and related noncarriers. They found much overlap in CSF protein changes between individuals with presymptomatic FAD and those with late-onset AD.

ASSOCIATION OF SEQUENCE ALTERATIONS IN THE PUTATIVE PROMOTER OF RAB7L1 WITH A REDUCED PARKINSON DISEASE RISK

Gan-Or et alArticle examine whether PARK16, which was recently identified as a protective locus for Parkinson disease (PD), is also associated with PD in the genetically homogeneous Ashkenazi Jewish population. Their data demonstrate that specific single-nucleotide polymorphism variations and haplotypes in the PARK16 locus are associated with reduced risk for PD.

FULMINANT POSTPARTUM CEREBRAL VASOCONSTRICTION SYNDROME

Fugate and colleaguesArticle raise awareness of the potentially adverse consequences of postpartum cerebral vasoconstriction, which is typically considered benign and self-limited, by describing 4 fulminantly fatal cases. Postpartum vasoconstriction can be fatal, with rapid progression of vasoconstriction, ischemia, and brain edema. Clinicians need to be aware of the potential consequences of this condition.

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

341 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs